Trump Signs Order to Fast‑Track Psychedelic Review, Allocates $50 Million

**TL;DR** President Trump signed an executive order to speed federal review of psychedelics such as ibogaine, directing HHS to allocate at least $50 million to states with treatment programs and prompting the FDA to issue national‑priority vouchers for three psychedelics this week.

**Context** Ibogaine, derived from a West African shrub, has been used in traditional Bwiti ceremonies and is explored by some veteran groups for post‑traumatic stress. Despite anecdotal reports, it remains a Schedule I substance with noted cardiac safety concerns. Recent bipartisan interest has grown, with Health Secretary Robert F. Kennedy Jr. previously pledging to ease medical access.

**Key Facts** The executive order instructs the Department of Health and Human Services to distribute no less than $50 million to states that have enacted or are developing psychedelic treatment initiatives for serious mental illness. This week the FDA will release national‑priority vouchers for three psychedelics, enabling accelerated approval if the drugs align with current national health priorities. The order also calls on federal agencies to relax restrictions on substances like ibogaine to facilitate research and potential therapeutic use.

**What It Means** Preliminary open‑label studies, such as a 2021 cohort of 27 veterans with PTSD, have reported symptom improvements after ibogaine administration, but these designs lack randomization and control groups, so observed changes may reflect correlation rather than causation. Rigorous evidence remains limited; no large‑scale randomized controlled trials of ibogaine for psychiatric conditions have been completed in the United States, primarily due to safety monitoring requirements. Practical takeaways for patients and clinicians include the possibility of earlier access to investigational psychedelics through state programs, while emphasizing the need for informed consent, cardiac screening, and participation in monitored trials. Watch for the FDA’s voucher issuance this week, subsequent state grant allocations, and any upcoming clinical trial announcements that could clarify efficacy and safety profiles.